Interaction of Transforming Growth Factor ß (TGFß) with Proteinase 3

  • J. Kekow
  • E. Csernok
  • C. Szymkowiak
  • W. L. Gross
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 421)


TGFß is a multifunctional cytokine modulating onset and course of autoimmune diseases as shown in experimental models. Aim of this study was to investigate possible interactions of TGFß with lysosomal enzymes identified as ANCA autoantigens (e.g. proteinase 3, PR3). This included TGFß effects on the translocation the lysosomal enzymes to the cell surface ofpolymorphonuclear cells (PMN), and the presumabe activation of non bioactive, latent TGFß by these enzymes. Flow cytometry analysis showed TGFß1 to be a potent translocation factor for PR3 comparable with other neutrophil activating factors such as irtterleukin 8 (1 L8). The PR3 membrane expression on primed PMN increased by up to 51% after incubation with TGFß1. PR3 itself was revealed as a potent activator of latent TGFß, thus mediating bioeffects of this cytokine. Patients with various types of systemic vasculitis (SV) showed marked TGFß overexpression correlating with disease. Mean TGFßI plasma levels in the ANCA associated vasculitis (AAV) patients ranged from 8.9 (Wegeners granulomatosis, WG) to 13.3 ng/ml (Churg-Strauss syndrome, CSS) (control: 4.2 ng/ml, p<0.01) while TGFß2 levels were not elevated. Our findings, together with other features of TGFß’s such as induction of angiogenesis and its strong chemotactic capacity, indicate that TGFß might serve as a proinflammatory factor in SV, especially in AAV.


Rheumatoid Arthritis Lysosomal Enzyme Systemic Vasculitis ANCA Associate Vasculitis Vasculitis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wahl, S.M. 1994. Transforming growth factor beta: the good, the bad, and the ugly. J. Exp. Med. 180: 1587–1590.PubMedCrossRefGoogle Scholar
  2. 2.
    Kekow, J. and G.J. Wiedemann. 1995. Transforming growth factor 13: A cytokine with multiple actions in oncology and potential clinical applications (Review). Int. J. Oncol. 7: 177–182.PubMedGoogle Scholar
  3. 3.
    Allen, J.B., C.L. Manthey, A.R. Hand, K. Ohura, L. Ellingsworth, and S.M. Wahl. 1990. Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor 13. J. Exp. Med. 171: 231–247.PubMedCrossRefGoogle Scholar
  4. 4.
    Brandes, M.E., J.B. Allen, Y. Ogawa, and S.M. Wahl. 1991. TGF-131 suppresses leukocyte recruitment and synovial inflammation in experimental arthritis. J. Clin. Invest. 87: 1108–1113.PubMedCrossRefGoogle Scholar
  5. 5.
    Szymkowiak, C., I. Mons, W.L. Gross, and J. Kekow. 1995. Determination of transforming growth factor 13 2 determination in human blood samples by ELISA. J. Immunol. Methods 184: 263–271.PubMedCrossRefGoogle Scholar
  6. 6.
    Gross, W.L., E. Csernok, and B.K. Flesch. 1993. `Classic’ anti-neurophil cytoplasmic autoantibodies (cANCA), ‘Wegener’s autoantigen’ and their immunopathogenic role in Wegener’s granulomatosis. Autoimmunity 6:171–184.Google Scholar
  7. 7.
    Gross, W.L., W.H. Schmitt, and E. Csernok. 1993. ANCA and associated diseases: Immunodiagnostic and pathogenic aspects. Clin. Exp. hnmunol. 91: 1–12.CrossRefGoogle Scholar
  8. 8.
    Lyons, R.M., L.E. Gentry, A.F. Purchio, and H.L. Moses. 1990. Mechanism of activation of latent recombinant transforming growth factor beta I by plasmin. J. Cell Biol. 110: 1361–1367.PubMedCrossRefGoogle Scholar
  9. 9.
    Kekow, J. and W.L. Gross. 1997. Immunologic assessments. In: Diagnostics of vascular diseases. Priciples and technology. P. Lanzer and M. Lipton, editors. Berlin, Springer. 226–236.CrossRefGoogle Scholar
  10. 10.
    Kekow, J., W. Wachsman, J.A. Mc Cutchan, W.L. Gross, M. Zachariah, D.A. Carson, and M. Lotz. 1991. TGF-(3 and suppression of humoral immune responses in HIV infection. J. Clin. Invest. 87: 1010–1016.PubMedCrossRefGoogle Scholar
  11. 11.
    Kekow, J., W. Wachsman, J.A. MacCutchan, M. Cronin, D.A. Carson, and M. Lotz. 1990. Transforming growth factor 13 and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Prnc. Natl. Acad. Sci. U. S. A. 87: 8321–8325.CrossRefGoogle Scholar
  12. 12.
    Csernok, E., J. Lüdemann, W.L. Gross, and D.F. Bainton. 1990. Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener’s granulomatosis. Am. J. Pathos. 137: 1113–1120.Google Scholar
  13. 13.
    Csernok, E., M. Ernst, W. Schmitt, D.F. Bainton, and W.L. Gross. 1994. Activated neutrophile express proteinase 3 on their plasma membrane in vitro and in vivo. Clin. Exp. Immunol. 95: 244–250.PubMedCrossRefGoogle Scholar
  14. 14.
    Leid, R.W.. B.E. Ballieux, I. van der Heijden, C. Kleyburg van der Keur, E.C. Hagen. L.A. van Es. F.J. Van der Woude, and M.R. Daha. 1993. Cleavage and inactivation of human CI inhibitor by the human leukocyte proteinase, proteinase 3. Eur J. lmmunol. 23: 2939–2944.CrossRefGoogle Scholar
  15. 15.
    Kekow, J., C. Szymkowiak, and W.L. Gross. 1992. Involvement of cytokines in granuloma formation within primary systemic vasculitis. In: New advances on cytokines. S. Romagnani. T.R. Mosmann, and A.K. Abbas, editors. New York, Raven Press. 341–348.Google Scholar
  16. 16.
    Deguchi, Y., N. Shibata. and S. Kishimoto. 1990. Enhanced expression of the tumour necrosis tàctor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin. Exp Immunol. 81: 311–314.PubMedCrossRefGoogle Scholar
  17. 17.
    Gross, W.L., S. Hauschild, and N. Mistry. 1994. The clinical relevance of ANCA in vasculitis. Clin. Exp. Immunol. 93: 7–11.CrossRefGoogle Scholar
  18. 18.
    McCartney Francis, N.L. and S.M. Wahl. 1994. Transforming growth factor beta: a matter of life and death. J. Leukoc. Biol. 55: 401–409.PubMedGoogle Scholar
  19. 19.
    Border, W.A., N.A. Noble, T. Yamamoto, J.R. Harper, Y. Yamaguchi. M.D. Pierschbacher, and E. Ruoslahti. 1992. Natural inhibitor of transforming growth factor-13 protects against scarring in experimental kidney disease. Nature 360: 361–364.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • J. Kekow
    • 1
  • E. Csernok
    • 2
  • C. Szymkowiak
    • 2
  • W. L. Gross
    • 2
  1. 1.Clinic of RheumatologyOtto von Guericke University of MagdeburgVogelsangGermany
  2. 2.Department of Clinical Rheumatology and Rheumaklinik Bad Bramstedt GmbHMedical University of LübeckLübeckGermany

Personalised recommendations